AZN vs IVF

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic 99% decline in share price over the last year. A critical liquidity crisis is evident with a Current Ratio of 0.12 and a Quick Ratio of 0.07, indicating an inability to meet short-term obligations. Negative book value (P/B -0.09) and a massive earnings miss of -158.3% suggest a high risk of insolvency. Despite modest revenue growth, the operational losses and technical collapse make this a high-risk speculative asset.